Now Is A Good Time To Buy Biodexa Pharmaceuticals Plc ADR (NASDAQ: BDRX)

During the last session, Biodexa Pharmaceuticals Plc ADR (NASDAQ:BDRX)’s traded shares were 0.76 million, with the beta value of the company hitting 1.42. At the end of the trading day, the stock’s price was $5.72, reflecting an intraday gain of 48.57% or $1.87. The 52-week high for the BDRX share is $220.25, that puts it down -3750.52 from that peak though still a striking 38.81% gain since the share price plummeted to a 52-week low of $3.50. The company’s market capitalization is $3.32M, and the average intraday trading volume over the past 10 days was 35470.0 shares, and the average trade volume was 161.31K shares over the past three months.

Biodexa Pharmaceuticals Plc ADR (NASDAQ:BDRX) trade information

Biodexa Pharmaceuticals Plc ADR (BDRX) registered a 48.57% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 48.57% in intraday trading to $5.72, hitting a weekly high. The stock’s 5-day price performance is 17.70%, and it has moved by -19.09% in 30 days. Based on these gigs, the overall price performance for the year is -91.80%. The short interest in Biodexa Pharmaceuticals Plc ADR (NASDAQ:BDRX) is 13762.0 shares and it means that shorts have 0.03 day(s) to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Biodexa Pharmaceuticals Plc ADR (BDRX) estimates and forecasts

Statistics show that Biodexa Pharmaceuticals Plc ADR has outperformed its competitors in share price, compared to the industry in which it operates. Biodexa Pharmaceuticals Plc ADR (BDRX) shares have gone down -79.20% during the last six months, with a year-to-date growth rate more than the industry average at 98.79% against 18.00.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 86.34%.

BDRX Dividends

Biodexa Pharmaceuticals Plc ADR is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Biodexa Pharmaceuticals Plc ADR (NASDAQ:BDRX)’s Major holders

Data provided on Sep 30, 2024 indicates that Fidelity NASDAQ Composite Index Fund owns about 78.0 shares. This amounts to just over 0.01 percent of the company’s overall shares, with a $517.0 market value.